Wednesday, August 26, 2026 In this video interview by UroToday, Dr. Michael Ong the PR26 TRIPLE-SWITCH study chair, describes the trial design, a phase 3 study randomizing patients with metastatic hormone-sensitive prostate cancer and PSA of 0.2 or above at six to twelve months of ADT plus any ARPI to either continue doublet therapy or add six cycles of docetaxel. The primary endpoint is overall survival; sample size is 830 patients. The rationale is that 50 to 68% of patients achieve undetectable PSA on doublet alone, potentially sparing them chemotherapy, while persistent PSA elevation identifies those with androgen insensitivity who may benefit from docetaxel.The drug being studied (docetaxel) is a type of chemotherapy drug that has been used for the treatment of prostate cancer, but it is not clear if it can offer better results than standard treatment for these patients. Docetaxel chemotherapy disrupts cell microtubules, targeting both testosterone dependent and independent mechanisms. While clinicians recommend hormone therapy for metastatic prostate cancer, there is a question about who benefits from the early addition of chemotherapy, with prior data suggesting that aggressive tumours may benefit the most. Find the interview here>PR26 TRIPLE-SWITCH trail was co-developed with our US partners the SWOG cancer research network. For PR26 patient trial information >
